High-Alert & Look-Alike/Sound-Alike (LASA) Medications
High-alert/risk medications and look-alike/sound-alike (LASA) medications.
High-alert and look-alike/sound-alike (LASA) medications make up 4.0% of the PTCE and sit inside the Patient Safety and Quality Assurance domain. High-alert drugs are those that carry a heightened risk of significant patient harm when used in error, and LASA pairs are drugs whose names look or sound so similar that they get mixed up during ordering, filling, or dispensing. The exam tests whether you can recognize the specific drugs on these lists and the extra safeguards each one requires.
The ISMP High-Alert Medication List
The Institute for Safe Medication Practices (ISMP) maintains the list of high-alert medications for acute care settings, most recently updated in January 2024. Core members include insulin (all forms, with U-500 singled out for special emphasis), anticoagulants (heparin, warfarin, and the direct oral anticoagulants), opioids on every route (oral, IV, transdermal, sublingual), chemotherapy agents, neuromuscular blockers, and concentrated electrolytes such as potassium chloride for injection and hypertonic sodium chloride greater than 0.9%. The 2024 update added tranexamic acid injection to the list. A common classroom mnemonic is "PINCH": Potassium (and other electrolytes), Insulin, Narcotics/opioids, Chemotherapy, Heparin/anticoagulants.
High-alert does not mean these drugs cause errors more often — it means an error with them is far more likely to seriously harm or kill the patient.
What "Look-Alike/Sound-Alike" Actually Means
LASA errors happen when two drug names are close enough to be confused during prescribing, transcription, or picking from the shelf. Classic exam pairs include hydrALAZINE (a vasodilator) vs. hydrOXYzine (an antihistamine), predniSONE vs. prednisoLONE, DOBUTamine vs. DOPamine, vinBLAStine vs. vinCRIStine, buPROPion (antidepressant) vs. busPIRone (anxiolytic), and metFORMIN vs. metroNIDAZOLE. The danger is compounded when confused drugs also share overlapping strengths or storage locations. LASA confusion can involve the generic name, the brand name, or a brand/generic crossover.
Confirm the drug against the NDC and the indication, not just the first few letters of the name.
Extra Safeguards for High-Alert Drugs
Because the consequence of an error is severe, high-alert medications get layered safeguards beyond normal workflow: independent double checks by a second person, standardized concentrations, auxiliary warning labels, storage separation, and removal of concentrated electrolytes (especially KCl injection) from general floor stock. Insulin and heparin — two of the most error-prone high-alert drugs — are frequently confused with each other because both are dosed in "units" and are often stored near one another, so many pharmacies physically separate them and require a second check.
Must-Know for the Exam
- ✓ISMP maintains the high-alert medication list; the acute care list was updated January 2024
- ✓PINCH = Potassium/electrolytes, Insulin, Narcotics/opioids, Chemo, Heparin/anticoagulants
- ✓Insulin U-500 gets special emphasis because of its concentrated strength
- ✓Concentrated potassium chloride for injection should not be kept in general floor stock
- ✓Classic LASA pairs: hydrALAZINE/hydrOXYzine, predniSONE/prednisoLONE, DOPamine/DOBUTamine, vinBLAStine/vinCRIStine
- ✓High-alert means high harm-severity if an error occurs, not high error-frequency
- ✓Insulin and heparin are commonly confused because both are dosed in units
- ✓Independent double checks are a primary safeguard for high-alert medications
Common Exam Mistakes
- ✗Thinking "high-alert" means the drug causes errors more often, rather than causing worse harm when an error occurs
- ✗Confusing insulin and heparin because both are measured in units
- ✗Mixing up hydrALAZINE (blood pressure) with hydrOXYzine (antihistamine/anxiety)
- ✗Assuming LASA only refers to sound-alike names, ignoring look-alike packaging and shelf placement
- ✗Picking a drug off the shelf by name alone instead of verifying the NDC
Quiz yourself on High-Alert & Look-Alike/Sound-Alike (LASA) Medications
Test what you just read — instant feedback on every question.
Start High-Alert & Look-Alike/Sound-Alike (LASA) Medications Practice Quiz →Key Concepts — Part 1
1. Which of the following medications is considered a high-alert medication because even a correctly prepared dose carries a significant risk of serious harm if an error occurs?
Insulin
Insulin is on ISMP's high-alert medication list because dosing errors (even small ones) can cause severe hypoglycemia; the other options are generally low-risk medications where errors are less likely to cause serious harm.
2. A technician is restocking an automated dispensing cabinet and finds vials of concentrated potassium chloride injection mixed in with other general IV additive vials on an open shelf. What is the appropriate action?
Segregate the concentrated potassium chloride and alert the pharmacist, since it is a high-alert medication that should be stored separately from general stock
Concentrated potassium chloride injection is a classic ISMP high-alert medication that has caused fatal errors when confused with other IV solutions; it should be stored separately (often removed from general floor stock entirely) with clear warning labeling. Leaving it mixed in, diluting it without authorization, or ignoring the issue are not appropriate technician actions.
3. Which of these is a recognized LASA (look-alike/sound-alike) pair, commonly written with Tall Man lettering as clonIDine and clonazePAM?
An antihypertensive and an anticonvulsant/anxiolytic that are frequently confused due to similar names
Clonidine (an antihypertensive) and clonazepam/Klonopin (a benzodiazepine anticonvulsant/anxiolytic) are well-known LASA drugs due to similar spelling and sound; Tall Man lettering (clonIDine / clonazePAM) helps differentiate them. They are different drug classes entirely, not duplicate formulations or supplements.
4. Celebrex, Celexa, and Cerebyx are frequently cited together in pharmacy safety training as an example of:
A three-way LASA (look-alike/sound-alike) risk requiring extra verification
Celebrex (an NSAID), Celexa (an antidepressant), and Cerebyx (an anticonvulsant) are unrelated drugs that are frequently mixed up due to similar spelling and sound, making them a textbook multi-drug LASA risk. They are not related therapeutically and are not exempt from safety checks.
5. Humalog and Humulin are considered a LASA risk primarily because:
They are both insulin products with similar names but different onset/duration profiles, so a mix-up can cause serious dosing errors
Humalog (rapid-acting) and Humulin (regular/NPH, slower-acting) insulins have similar brand names but different time-action profiles; confusing them can lead to dangerous mistiming of insulin action. They are not interchangeable, and both are injectable, not oral.
6. Tall Man lettering formats DOPamine and DOBUTamine to help distinguish two medications that are:
Both vasoactive IV medications with similar spellings but different effects, used in high-alert critical care settings
Dopamine and dobutamine are both IV vasoactive/inotropic drugs used in critical care with similar spellings but different hemodynamic effects, making a mix-up potentially dangerous; Tall Man lettering (DOPamine/DOBUTamine) highlights the differing suffix. They are not antihistamines and are not interchangeable.
7. PredniSONE and predniSOLONE are distinguished with Tall Man lettering mainly because:
Their similar names could lead to selecting the wrong product, even though they are related corticosteroids with different formulations/uses
Prednisone and prednisolone are related corticosteroids but not identical products (prednisone is a prodrug converted to prednisolone in the liver); their near-identical spelling makes them a name-confusion risk worth Tall Man lettering. Neither is a controlled substance, and both require a prescription.
8. HYDROcodone and OXYcodone are examples of medications where Tall Man lettering is used mainly to prevent confusion between:
Two different opioid analgesics with different potencies, since a mix-up could cause under- or over-treatment of pain or overdose
Hydrocodone and oxycodone are both opioid analgesics but differ in potency and formulation options; the similar name endings create a real risk of selecting the wrong opioid, which is significant given they're also high-alert controlled substances. They are not the same product in different forms.
9. In pharmacy safety terminology, a 'high-alert medication' is best defined as a drug that:
Carries a heightened risk of causing significant patient harm when used in error, even though the errors themselves may not be more frequent than with other drugs
ISMP defines high-alert medications by the severity of harm if an error occurs, not by how often errors happen with that drug. Cost, dispensing-only-by-pharmacist rules, and generic availability are unrelated to the high-alert designation.
10. A technician notices that two different-strength stock bottles of the same drug from the same manufacturer have nearly identical packaging, differing only in a small font size for strength. What should the technician do?
Physically separate the bottles, apply differentiating auxiliary labels, and inform the pharmacist of the packaging risk
Look-alike packaging between different strengths of the same drug is a recognized error risk; the appropriate response is to separate stock, add clear differentiating labels, and flag it to the pharmacist so the pharmacy can adjust storage or shelf placement. Different strengths are not interchangeable, and a technician should not unilaterally relabel or return stock without pharmacist involvement.
Key Concepts — Part 2
1. Why is warfarin classified as a high-alert medication?
It has a narrow therapeutic index and bleeding risk, so small dosing errors or interactions can cause serious harm
Warfarin's narrow therapeutic index means the difference between an effective dose and a dangerous (bleeding or clotting) dose is small, and it interacts with many drugs and foods -- this is why it's high-alert. It is not a controlled substance, and it is manufactured commercially, not only compounded.
2. A prescriber writes an order for methotrexate to be taken daily for rheumatoid arthritis, when the standard regimen is weekly. Why is this scenario frequently used to illustrate high-alert medication risk?
Because daily (instead of weekly) dosing of methotrexate for non-oncologic use has caused fatal toxicity in real cases, making it a well-documented high-alert error pattern
Low-dose methotrexate for rheumatoid arthritis and other non-cancer conditions is dosed weekly, not daily; accidental daily dosing is a well-known, sometimes fatal error, which is why methotrexate frequency is a classic high-alert teaching example. It is a real, common RA treatment, and this risk applies to commercially dispensed tablets, not just compounds.
3. Chemotherapy agents are classified as high-alert medications primarily because of:
Their narrow therapeutic index and potential for severe, sometimes irreversible toxicity from dosing errors
Chemotherapy agents have a narrow window between an effective and a toxic dose, and errors can cause severe, sometimes irreversible harm -- hence their high-alert status and special handling requirements (including USP <800> precautions). They are often expensive, may be given by various routes, and do require special handling, not none.
4. Why are neuromuscular blocking agents (e.g., succinylcholine) considered high-alert and typically stored separately with a distinct warning?
Accidental administration outside a monitored setting can cause paralysis and respiratory arrest, which is why they must be clearly segregated from other stock
Neuromuscular blockers paralyze skeletal muscles, including those needed for breathing; if given inadvertently outside a setting with ventilatory support, the result can be fatal -- this severity is why they're flagged high-alert and stored/labeled distinctly. They are not low-risk, and patient mix-ups with these drugs are especially dangerous.
5. Lamictal and Lamisil are an example of a LASA pair involving:
An anticonvulsant/mood stabilizer and an antifungal medication that are unrelated in use but similar in name
Lamictal (lamotrigine, used for seizures/bipolar disorder) and Lamisil (terbinafine, an antifungal) have similar-sounding names despite being completely unrelated in therapeutic use, which is exactly what makes LASA errors dangerous -- the consequences of the mix-up are unpredictable. They are not related formulations of one drug.
6. Zyprexa and Zyrtec are frequently cited as a LASA pair because:
Despite very similar names, one is an antipsychotic and the other is an antihistamine, so a mix-up could have serious clinical consequences
Zyprexa (olanzapine, an antipsychotic) and Zyrtec (cetirizine, an OTC antihistamine) sound alike but treat completely different conditions, so confusing them could mean a patient receives a powerful psychiatric medication instead of an allergy pill (or vice versa). Neither is a controlled substance, and they are not the same drug.
7. Norvasc and Navane are an older but still-cited LASA example involving:
An antihypertensive calcium channel blocker and an antipsychotic, whose similar brand names create confusion risk
Norvasc (amlodipine, a calcium channel blocker for hypertension) and Navane (thiothixene, an antipsychotic) have similar-sounding brand names despite treating entirely different conditions, illustrating why name similarity alone -- independent of drug class -- is a recognized error risk. They are not the same drug class or formulation.
8. A pharmacy stocks both U-100 (standard) and U-500 (concentrated) insulin. Why is this combination specifically flagged as high-alert risk?
Because the concentrations differ five-fold, and using U-500 insulin with a standard U-100 syringe (or vice versa) can cause a severe dosing error
U-500 insulin is five times more concentrated than standard U-100 insulin; using the wrong syringe or misreading the concentration can lead to a massive overdose or underdose, which is why U-500 requires special handling, storage, and dedicated syringes. Both concentrations are real, currently manufactured insulins, and pharmacies are expected to store/label them distinctly.
9. Which factor most commonly contributes to LASA (look-alike/sound-alike) medication errors?
Similarity in spelling, pronunciation, or packaging that leads to misreading a handwritten or verbal order, or misselecting stock
LASA errors are driven by name or packaging similarity combined with factors like illegible handwriting, verbal order mishearing, or visual mix-ups on the shelf. Locked storage, e-prescribing, and consistent bar code scanning are all error-prevention measures, not contributing causes.
10. While filling a prescription for hydroxyzine 25 mg, a technician scans the stock bottle and the system flags an NDC mismatch -- the bin was actually restocked with hydralazine. What should the technician do?
Stop, do not dispense from that bin, and alert the pharmacist that the stock was mislabeled
A bar code mismatch is a critical safety flag and should never be overridden casually -- hydroxyzine and hydralazine are an unrelated LASA pair. The technician should stop, avoid dispensing from the mislabeled bin, and notify the pharmacist so the stock can be corrected and the correct product located.
Ready to test your knowledge?
Practice questions with instant feedback and explanations.
Take a PTCB Practice Test →